ArticleESMO open2026
Zolbetuximab plus chemotherapy versus immune checkpoint inhibitor regimens by programmed death-ligand 1 combined positive score in locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: a Bayesian network meta-analysis.
Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn this network meta-analysis (NMA), efficacy of first-line (1L) zolbetuximab and immune checkpoint inhibitors (ICIs) was compared across programmed death-ligand 1 [PD-(L)1] combined positive score (CPS) levels in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma in global trials. MATERIALS AND
methodsStudies evaluating zolbetuximab or ICIs plus chemotherapy as 1L treatments among adults with LA unresectable or mG/GEJ adenocarcinoma were included. A Bayesian fixed-effects NMA compared overall survival (OS) and progression-free survival (PFS) across treatments in PD-(L)1 CPS subgroups (CPS ≥1 to <5; ≥5 to <10; or ≥10). Because PD-(L)1 CPS is a biologically and clinically validated treatment effect modifier for ICIs, CPS-specific hazard ratios were used for ICIs but not zolbetuximab, which targets claudin 18 isoform 2 (CLDN18.2). Sensitivity analyses of PD-(L)1 CPS ≥10 leveraged patients with optimal zolbetuximab exposure-those who did not experience nausea/vomiting leading to inadequate dose exposure or discontinuation.
resultsFive regimens (zolbetuximab, pembrolizumab, tislelizumab, or nivolumab plus chemotherapy, and chemotherapy alone) were included. In PD-(L)1 CPS ≥1 to <5, zolbetuximab showed similar or numerically favorable OS and PFS versus ICIs. In PD-(L)1 CPS ≥5 to <10, zolbetuximab had numerically favorable OS and PFS versus ICIs. In PD-(L)1 CPS ≥10, ICIs had numerically favorable OS and PFS versus zolbetuximab. However, in sensitivity analyses, among patients with optimal zolbetuximab exposure, zolbetuximab showed similar OS and PFS to ICIs.
conclusionsThese findings support a biomarker-informed treatment approach in human epidermal growth factor receptor 2 (HER2)-negative, CLDN18.2-positive advanced gastric/GEJ adenocarcinoma. In PD-(L)1 CPS ≥1 to <10, zolbetuximab plus chemotherapy demonstrated consistent efficacy and may represent a relevant option beyond PD-(L)1-driven selection. In CPS ≥10, zolbetuximab remained clinically meaningful, with efficacy comparable to select ICI-based regimens when exposure is optimized. Results should be interpreted cautiously given these are indirect comparisons and warrant confirmation in prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.